Optionale Produktanalyse
Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
Align Technology Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $10.5B |
|---|
| Revenue (ttm) | 4.1B |
|---|
| Net income (ttm) | 413.6M |
|---|
| EPS (ttm) | $5.76 |
|---|
| Shares out | 71M |
|---|
| P/E (trailing) | 26.6x |
|---|
| P/E (forward) | 11.6x |
|---|
| Volume | 1,083,301 |
|---|
| Beta | 1.67 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $3.95B | $3.73B | $3.86B | $4.00B | $4.03B | +0.5% |
| Gross profit | $2.94B | $2.63B | $2.71B | $2.80B | $2.71B | -2.0% |
| Operating income | $976.4M | $642.6M | $643.3M | $607.6M | $545.8M | -13.5% |
| Net income | $772.0M | $361.6M | $445.1M | $421.4M | $410.4M | -14.6% |
| EPS (diluted) | $9.69 | $4.61 | $5.81 | $5.62 | $5.65 | -12.6% |
| EBITDA | $1.09B | $779.8M | $643.3M | $816.8M | $765.9M | -8.3% |
| R&D | $250.3M | $305.3M | $346.8M | $364.2M | $369.9M | +10.3% |
| SG&A | $1.71B | $1.67B | $1.70B | $1.76B | $1.76B | +0.7% |
Recent company headlines from major financial publishers.
The Base scenario assumes modal revenue compounding in low single digits, supported by steady teen Invisalign case adoption and stable international scanner installations. Under this path, operating margins expand modestly as European manufacturing automation takes effect, but unallocated corporate overhead limits operating leverage. Disconfirmation would occur if clear aligner volume contracts or operating margins fail to hold baseline levels by the end of FY2027. At an assessed probability of 60.0%, this scenario yields a target of $121.31, representing an expected return of -17.8% from $147.61 (as of 2026-09-18).
The Bull scenario reflects accelerated adolescent and teen clear aligner penetration, rapid adoption of the latest iTero intraoral scanner platform, and faster international expansion across underpenetrated emerging dental markets. Fixed-cost absorption in manufacturing hubs accelerates operating margin expansion toward historical peaks. This path would be disconfirmed if adult case deferrals spread to the teen cohort or if scanner placement cadence decelerates. With an assessed probability of 20.0%, this outcome supports a target of $121.34, offering a return of -17.8% from $147.61 (as of 2026-09-18).
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 8.7% | $135 | $138 | $142 | $146 | $151 |
| 9.7% | $126 | $128 | $130 | $133 | $136 |
| 10.7% | $118 | $120 | $121 | $123 | $126 |
| 11.7% | $112 | $113 | $114 | $116 | $117 |
| 12.7% | $106 | $107 | $108 | $109 | $111 |
Upcoming earnings date and setup when available.
Das Rating, das die veröffentlichte Research-Ausgabe des jeweiligen Monats trug. Ein Rating vergleicht den Kurs zum Analysezeitpunkt mit dem Fair Value; es ist kein Nachweis, ob die Einschätzung zutraf.
| Jahr | Jan | Feb | Mär | Apr | Mai | Jun | Jul | Aug | Sep | Okt | Nov | Dez |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
